Pfizer has spent years under pressure following the collapse of pandemic-era revenues. Yet beneath the headlines, the company's non-COVID business is strengthening, oncology is expanding through Seagen, and two highly respected directors—including former Vanguard CEO and CIO Tim Buckley—recently invested nearly $2 million of their own money. We examine whether Wall Street is overlooking one of healthcare's most compelling value opportunities.

Read entire article

Biohaven’s stock plunged after a brutal FDA rejection — but insiders didn’t blink. They bought millions of dollars’ worth of shares, doubled down on their pipeline, and kickstarted a leaner, more focused strategy. Bold turnaround play or biotech heartburn waiting to happen? Here's the FUNanc1al deep dive.

Read entire article

Insiders dropped $6M on Moderna stock. With a massive mRNA pipeline and deep-pocketed backers, is this biotech beast ready to roar again?

Read entire article